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Abstract
Lung cancer is the leading cause of cancer deaths worldwide. Expression of the p53 tumor suppressor protein is
frequently altered in tobacco-associated lung cancers. We studied chemopreventive effects of p53-modulating
agents, namely, CP-31398 and Prima-1, on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)–induced lung
adenoma and adenocarcinoma formation in female A/J mice. Seven-week-old mice were treated with a single dose
of NNK (10 μmol/mouse) by intraperitoneal injection and, 3 weeks later, were randomized to mice fed a control
diet or experimental diets containing 50 or 100 ppm CP-31398 or 150 or 300 ppm Prima-1 for either 17 weeks
(10 mice/group) or 34 weeks (15 mice/group) to assess the efficacy against lung adenoma and adenocarcinoma.
Dietary feeding of 50 or 100 ppm CP-31398 significantly suppressed (P < .0001) lung adenocarcinoma by 64% and
73%, respectively, after 17weeks andby47%and56%, respectively, after 34weeks. Similarly, 150or 300ppmPrima-1
significantly suppressed (P < .0001) lung adenocarcinoma formation by 56% and 62%, respectively, after 17 weeks
and 39% and 56%, respectively, after 34 weeks. Importantly, these results suggest that both p53 modulators cause a
delay in the progression of adenoma to adenocarcinoma. Immunohistochemical analysis of lung tumors from mice
exposed to p53-modulating agents showed a significantly reduced tumor cell proliferation and increased accumulation
of wild-type p53 in the nucleus. An increase in p21- and apoptotic-positive cells was also observed in lung tumors of
mice exposed to p53-modulating agents. These results support a chemopreventive role of p53-modulating agents in
tobacco carcinogen–induced lung adenocarcinoma formation.
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Introduction
Lung cancer is the leading cause of cancer mortality in both men and
women in the United States [1]. p53 is the most commonly mutated
gene in human lung cancer [2] in which the mutation frequency is
higher in lung cancers of smokers [3]. p53 is a stress-induced tumor
suppressor gene that plays a major role in multiple cellular functions
such as cell cycle arrest and apoptosis, including DNA damage repair
and cancer [4–6]. Nuclear localization is essential for the activity of
p53 as a transcription factor [7], where it evokes cell cycle arrest or
apoptosis through transcriptional activation of numerous effector
genes [7–9]. p53 mutations result in loss of p53 tumor suppressor
function and gain-of-function oncogenic mutations. About 50% of
human cancers acquire somatic p53 mutations during the course of
malignant conversion. Nonfunctional activity of p53 in cancer usu-
ally occurs in cancer by mutation, deletion, or inhibitory binding
with viral oncoproteins [10–12]. Most p53 mutations occur in the
DNA binding domain of the p53 protein, and about 80% are missense
point mutations. Wild-type p53 (wt-p53) may also be inactivated in
tumor tissues as a result of abnormal sequestration in the cytoplasm
where it is functionally mutated [13,14]. Electrophilic prostaglandins
produced by cyclooxygenase 2 have been shown to inhibit the wt-p53
activity by covalently binding to and impairing p53 in cytosol [15,16].
Over the past two decades, efforts have been made to restore or
enhance p53 function in tumor cells. High-throughput screening
has led to the identification of direct-acting inhibitors, such as a
COOH-terminal peptide of p53, and small molecules, such as CP-
31398, Prima-1, and MIRA-1 [17–21]. CP-31398, a styrylquinazoline
that emerged from in vitro screening, can stabilize p53, protect against
thermal denaturation, and maintain a monoclonal antibody 1620
epitope conformation in newly synthesized p53 [22] that restores a
wt-p53 DNA binding conformation on mutant p53 (mut-p53) to
suppress tumors in vivo [18]. CP-31398 was shown to promote stabi-
lization of the DNA binding domain of p53 and to restore the trans-
activation function of certain mut-p53 proteins both in vitro and in vivo
[18,20,23]. Studies from our laboratory demonstrated that CP-31398
inhibits intestinal polyp formation in APCmin/+ mice [24] and chemi-
cally induced colon cancers in a rat model [25] by reactivating p53.
Prima-1 is another small molecule identified for its restoration of
wild-type conformation and specific DNA binding to mut-p53 and
for its ability to trigger apoptosis; it has mut-p53–dependent antitumor
activity in vivo [26]. Previous reports have shown that Prima-1 inhibits
the growth of cell lines derived from various human tumor types in a
mut-p53–dependent manner [18,27].
Here, we have evaluated the chemopreventive efficacy of CP-
31398 and Prima-1 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
(NNK)–induced lung adenoma and adenocarcinoma formation in
female A/J mice to help elucidate whether direct-acting small mole-
cules that rescue/activate p53 can prevent lung cancer in these mice.
We chose the NNK-treated female A/J mouse model because these
mice develop lung adenomas and adenocarcinomas in a manner that
is similar to tobacco-induced lung cancer in humans and they are
widely used in evaluating chemopreventive efficacy [28–32]. Further-
more, we investigated the effect of p53 modulators during initiation,
including progression of early adenoma to adenocarcinoma by admin-
istrating these agents shortly after NNK treatment and well into the
stage(s) in which adenoma occur. Together, these results support a
chemopreventive role for direct-acting small molecules that rescue
and activate mut-p53 in preventing tobacco carcinogen–induced lung
adenocarcinoma formation.
Materials and Methods
Animals, Diets, Chemopreventive Agents, Chemicals,
and Reagents
All animal experiments were performed in accordance with
National Institutes of Health (NIH) guidelines and University of
Oklahoma Health Sciences Center Institutional Animal Care and
Use Committee–approved protocol (IACUC No. 09-067B). Female
A/J mice were obtained at 6 weeks of age from Jackson Laboratory
(Bar Harbor, ME). Ingredients for the semipurified diets were pur-
chased from Bio-Serv (Frenchtown, NJ) and stored at 4°C before diet
preparation. Diets were based on the modified American Institute of
Nutrition 76A (AIN-76A) diet containing 20% casein, 52% corn-
starch, 13% dextrose, 5% corn oil, 5% alphacel, 3.5% AIN mineral
mix, 1.2% AIN revised vitamin mix, 0.3% D,L-methionine, and
0.2% choline bitartrate. CP-31398 and Prima-1 (Figure 1A) were
kindly supplied by the National Cancer Institute, Division of Cancer
Prevention Repository (Bethesda, MD). Test agents were premixed
with a small quantity of casein and then blended into bulk diet using
a Hobart Mixer. Both control and experimental diets were prepared
weekly and stored in a cold room. The content of agent(s) in the
experimental diets was determined periodically in multiple samples
taken from the top, middle, and bottom portions of individual diet
preparations to ensure uniform distribution.
The cocktail of protease inhibitors was from Sigma (St Louis,
MO). NNK was synthesized and provided by the laboratory of
Dr Shantu Amin (Department of Pharmacology, Penn State Hershey,
Hershey, PA). Anti–wt-p53 (Catalog No. OP33) and anti–mut-p53
(Catalog No. OP29) were purchased from Calbiochem (La Jolla, CA).
Anti–poly(ADP-ribose) polymerase (PARP) and anti–caspase-3
were from Cell Signaling Technology (Beverly, MA). Anti-p21, anti–
phospho-retinoblastoma (pRb), anti-total Rb, and anti–β-actin were
from Santa Cruz Biotechnology (Santa Cruz, CA).
Experimental Bioassay
The experimental design is summarized in Figure 1B. Female A/J
mice at 6 weeks of age were purchased from Jackson Laboratory and
were maintained in the pathogen-free Rodent Barrier Animal Facility
at the University of Oklahoma Health Sciences Center. At 6 weeks
of age, mice were fed control irradiated AIN-76A modified diet. At
7 weeks of age, the mice intended for carcinogen treatment received
a single dose of 10 μmol (2.07 mg) NNK/mouse by intraperitoneal
injection. All mice were weighed once every 2 weeks until termina-
tion of the study. Three weeks after NNK treatment, groups of mice
(25 mice/group) were fed control AIN-76A or experimental diets
containing 50 or 100 ppmCP-31398 or 150 or 300 ppm Prima-1 until
termination. Mice were killed by CO2 asphyxiation followed by cervi-
cal dislocation after 17 weeks (10 mice/group) or 34 weeks (15 mice/
group) of exposure to test agents. At the time of sacrifice, lungs were
lavaged, perfused, and fixed in phosphate-buffered formalin, transferred
within 2 days to 70% alcohol, and evaluated under a dissecting micro-
scope for the number of tumors and tumor size. Tumors on the lung
surface were enumerated by at least two experienced readers, blinded to
sample identifiers, using a dissecting microscope. Tumor diameters
were measured using Fisher brand digital calipers.
Tumor Histology
Fixed lung samples were then embedded in paraffin, sectioned,
and stained with hematoxylin and eosin (H&E). H&E-stained lung
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sections from three separate sections cut at predetermined depths
were evaluated by a board-certified pathologist (Dr Stan Lightfoot,
Department of Pathology and VA Hospital, Oklahoma City, OK)
for the number of adenomas and adenocarcinomas. Tumors were
categorized according to criteria of the Mouse Models of Human
Cancers Consortium [33]. Adenomas were generally less than 5-mm-
diameter, well-circumscribed areas of proliferative cuboidal to columnar
cells lining an alveolus. Adenocarcinomas were typically >5 mm in
diameter and showed invasion and loss in alveolar architecture,
increased nuclear/cytoplasmic ratio, cellular atypia, a large mass of
undifferentiated cells, and nuclear pleomorphism.
Immunohistochemistry
The effects of CP-31398 and Prima-1 on expression of prolifer-
ating cell nuclear antigen (PCNA), p21, wt-p53, and mut-p53 were
evaluated in adenocarcinomas by immunohistochemistry (IHC).
Briefly, paraffin sections were deparaffinized in xylene, rehydrated
through graded ethanol solutions, and washed in phosphate-buffered
saline (PBS). Antigen retrieval was carried out by treating sections in
0.01 M citrate buffer (pH 6.0) for 30 minutes in a boiling water
bath. Endogenous peroxidase activity was quenched by incubation
in 3% H2O2 in PBS for 5 minutes. Nonspecific binding sites were
blocked by incubation with 2% BSA, and then sections were incu-
bated overnight at 4°C with 1:100 dilutions of monoclonal anti-
bodies against PCNA, p-21, wt-p53, or mut-p53. After several
washes with PBS, the slides were incubated with appropriate second-
ary antibody for 2 hours and then washed and incubated with avidin-
biotin complex reagent (Zymed Laboratories, Camarillo, CA). The slides
were rinsed with PBS, incubatedwith the chromogen 3-diaminobenzidine
for 3 minutes, and then rinsed and counterstained with hematoxylin.
Nonimmune rabbit Igs were substituted for primary antibodies as
negative controls. Slides were observed under an Olympus microscope
IX701, and digital computer images were recorded with an Olympus
DP70 camera.
Immunohistofluorescence
For immunohistofluorescence, after overnight incubation with
primary antibody of wt-p53 and mut-p53, the slides were washed
thrice with PBS for 5 minutes and then incubated with secondary
antibody tagged with tetramethyl rhodamine isothiocyanate (TRITC)
in the dark for 1 hour. Slides were then washed with PBS for 5 min-
utes thrice in the dark room and incubated with 4′,6-diamidino-2-
phenylindole (0.5 μg/ml) for 5 minutes. Slides were rinsed with
PBS and observed for fluorescence under fluorescein isothiocyanate/
TRITC filters using an Olympus microscope IX701, and digital com-
puter images were recorded with an Olympus DP70 camera.
Apoptosis Assay
Paraffin sections of 5-μm thickness were mounted on slides, rehy-
drated, and stained using the terminal deoxynucleotidyl transferase–
mediated deoxyuridine triphosphate nick end labeling (TUNEL)
method. TUNEL-positive cells were visualized by chromogenic
staining with 3-diaminobenzidine, and slides were counterstained
with malachite green. Stained apoptotic epithelial cells (a minimum
Figure 1. (A) Structure of CP-31398 and Prima-1. (B) Experimental protocol to assess the chemopreventive effects of CP-31398 and
Prima-1 in NNK-induced lung tumorigenesis in A/J mice. Eight-week-old mice were injected intraperitoneally with NNK (10 μmol/mouse)
and maintained on AIN-76A diet for 3 weeks. Three weeks after NNK injection, mice were fed control diet (AIN-76A) or diets containing
50 or 100 ppm of CP-31398 or 150 or 300 ppm Prima-1 and continued until the end of the study. At 20 weeks (10 mice/group) and at
37 weeks (15 mice/group) after NNK treatment, mice were killed and lungs were harvested for evaluation of lung tumors. Detailed
information has been given in Materials and Methods section.
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of 10 microscopic fields per section) were counted manually in a
double-blind fashion.
Western Blot Analysis of Protein Expression
Lung tumors harvested from mice from different treatment groups
were immediately frozen in liquid nitrogen and stored at −80°C for
further analysis. During the time of marker analysis, large tumors
were excised from the lungs, homogenized, and lysed in cold lysis
buffer (Sigma). After a brief vortexing, the lysates were separated by
centrifugation at 12,000g for 15minutes at 4°C, and protein concentra-
tions were measured with the Bio-Rad Protein Assay reagent (Bio-Rad,
Hercules, CA). An aliquot (50 μg protein/lane) of the total protein was
separated with 10% sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis and transferred to nitrocellulosemembranes. After blocking the
membranes with 5% milk powder, adenocarcinomas were probed for
expression of p21, total Rb, pRb–Ser-795, β-actin, PARP, caspase-3,
wt-p53, and mut-p53 in hybridizing solution (1:500, in TBS–Tween 20)
using the respective primary antibodies and then probed with their
appropriate HRP-conjugated secondary antibodies. Detection was per-
formed using the SuperSignal VWR West Pico Chemiluminescence
procedure (Pierce, Rockford, IL). The bands were captured on Ewen
Parker Blue sensitive X-ray films and quantified by densitometry.
We reprobed every blot for β-actin, but we present only one β-actin
blot from each of the two intervals of test agent exposure: 17 and
34 weeks.
Statistical Analysis
Differences in body weights among groups were analyzed by
analysis of variance. Adenoma and adenocarcinoma multiplicities
(number of tumors/mouse) are expressed as means ± SD. Protein
expression, proliferative indices, and apoptotic indices were expressed
as means ± SEM and were analyzed by unpaired t test with Welch
correction. Dose-response effects were analyzed by linear regression
analysis. Differences were considered statistically significant at P < .05.
Results
General Observations
Dose selection was based on our previous toxicity studies; CP-
31398 doses of up to ∼400 ppm and Prima-1 doses of up to
∼600 ppm were tolerable in rodent models when administered
chronically with AIN-76A diet for 9 weeks [25]. In the present
study, we applied 12.5% and 25% of the maximally tolerated dose
of CP-31398 and 25% and 50% of the maximally tolerated dose
of Prima-1 to assess the chemopreventive efficacy. Unlike Prima-1,
CP-31398 had been studied extensively for efficacy, pharmaco-
kinetics, and pharmacodynamics in rodents [34]. Administration
of 50 or 100 ppm CP-31398 or 150 or 300 ppm Prima-1 for
either 17 or 34 weeks did not cause any body weight loss or any
other histologic toxicity in major organ sites (data not shown).
Overall, chronic dietary administration of CP-31398 and Prima-1
for either 17 or 34 weeks did not induce any overt toxicities in
female A/J mice.
Dietary Administration of CP-31398 and Prima-1
Significantly Inhibited Lung Adenocarcinoma and Delayed the
Progression of Adenoma to Adenocarcinoma Formation
NNK-treated mice fed the control diet developed 100% tumor
incidence at 20 and 37 weeks after the carcinogen treatment (Fig-
ure 2, A and B). Control diet mice killed at 20 weeks after NNK
treatment showed an average of 6.7 ± 1.4 lung adenomas and 9.22 ±
2.2 lung adenocarcinomas (means ± SEM, reflecting 41.4% of the
tumors were adenomas and 58.6% were adenocarcinomas; Figure 2,
C and D). Mice fed the control diet and killed at 37 weeks after
NNK treatment showed 3.8 ± 1.1 adenomas and 19.4 ± 3.1 adenocar-
cinomas (16.4% of the tumors were adenomas and 83.6% were
adenocarcinomas; Figure 2, E and F ), reflecting an increased pro-
gression of adenomas to adenocarcinomas. The effects of CP-31398
and Prima-1 on lung adenoma and adenocarcinoma multiplicities are
summarized in Figure 2,C to F . Mice administered 50 ppmCP-31398
for 17 weeks showed a slightly higher number of lung adenomas,
whereas lung adenocarcinomas were significantly (P < .0001) sup-
pressed by 64% or 73%, respectively, at the 50- or 100-ppm doses.
A similar trend was observed in mice exposed to CP-31398 for
34 weeks; NNK-induced adenocarcinomas were inhibited by 47% to
56% at the two doses (P < .0001; Figure 2, E and F ). However,
we observed a slight increase in the lung adenomas, reflecting some
delay in tumor progression from adenoma to adenocarcinoma in the
CP-31398–treated mice.
Administration of 150 or 300 ppm Prima-1 significantly sup-
pressed NNK-induced total lung adenocarcinoma formation by
57% or 62% (P < .0001), respectively, after 17 weeks of exposure
and by 39% or 56% (P < .0001), respectively, after 34 weeks of ex-
posure. As with administration of the lower (50 ppm) dose of CP-
31398, administration of the lower (150 ppm) dose of Prima-1 also
slightly increased the number of NNK-induced lung adenomas. We
observed that there is no significant difference in lung spontaneous
tumors in mice fed with control diet (adenomas, 0.4 ± 0.55/mouse;
N = 6) compared to mice fed with CP-31398 and Prima-1 (adeno-
mas, 0.2 ± 0.45; P = .27).
Effect of p53 Modulators on Apoptotic Index
Figure 3, B and G , summarizes the apoptotic effect of p53 mod-
ulators in lung adenocarcinomas of mice exposed for 34 weeks to
100 ppm CP-31398 or 300 ppm Prima-1. Apoptotic or TUNEL-
positive cells are stained dark brown and nonapoptotic cells are
counterstained with methyl green. Quantification of apoptotic stain-
ing revealed an apoptotic index of 10 ± 2.3 (mean ± SEM) TUNEL-
positive cells in adenocarcinomas from mice fed the control diet
as compared with an apoptotic index of 50 ± 6.1 or 35 ± 6
(mean ± SEM) TUNEL-positive cells in lung adenocarcinoma of
mice fed 100 ppm CP-31398 or 300 ppm Prima-1, respectively,
accounting for an increase in the apoptotic index of several fold by
both agents.
Modulation of PCNA, p21, mut-53, and wt-p53 Expression
by CP-31398 and Prima-1 in NNK-Induced
Lung Adenocarcinomas
Effects of 100 ppm CP-31398 and 300 ppm Prima-1 on lung
adenocarcinoma cell proliferation were assessed through labeling of
PCNA-positive cells (Figure 3C ). PCNA labeling index was signifi-
cantly lowered in tumors from CP-31398 or Prima-1–treated mice
compared with tumors from mice fed a control diet. The quantifica-
tion of PCNA staining showed a labeling index of 72 ± 5.8 (mean ±
SEM) in adenocarcinomas from mice fed a control diet as compared
with 30 ± 3.4 and 45 ± 3.5 (means ± SEM) in those from animals fed
CP-31398 or Prima-1, accounting for a decrease in the proliferation
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index by 60% (P < .0001) or ∼38% (P < .0002), respectively
(Figure 3H ).
As shown in Figure 3D, expression of p21 was significantly re-
duced in lung adenocarcinomas of mice fed control diets, whereas
dietary administration of CP-31398 and Prima-1 resulted in a signifi-
cant increase in p21 protein expression levels in lung tumors. Fig-
ure 3, E and F , summarizes the expression of mut-p53 and wt-p53
in lung tumors of mice exposed to control diet or p53-modulating
agents. We have not observed any significant differences in the ex-
pression of mut-p53 between the lung tumors from mice fed the
control diet versus either of the p53-modulating agents. However,
a significant increase in the expression of wt-p53 was observed in
the lung tumors of mice treated with p53 modulators. From the
immunofluorescence histochemistry analysis as shown in Figure 4,
we observed an increased localization of wt-p53 in the nucleus of the
lung tumors from mice fed 100 ppm CP-31398 when compared to
those from mice fed the control diet. We also observed chromatin
condensation and apoptosis of nuclei in tumor cells of mice fed the
CP-31398 diet.
Western Blot Analysis of wt-p53, mut-p53, p21WAF1/CIP1,
Cleaved Caspase-3, and PARP Modulation by p53 Modulators
Expression of wt-p53, mut-p53, p21WAF1/CIP1, cleaved caspase-3,
and PARP was analyzed further by Western blot analysis. As shown
in Figure 5, A and B, CP-31398 and Prima-1 caused significant in-
duction of p21WAF1/CIP1 expression in lung tumors harvested from
mice after 17 or 34 weeks of exposure. CP-31398 caused a greater
induction of p21WAF1/CIP1 than did Prima-1. Figure 5B shows pro-
teolytic cleavage of caspase-3 and decrease in PARP in mice fed
CP-31398 compared with mice fed the control diet. The cleavage of
caspase-3 was observed only in late-stage tumors and in mice fed the
high dose of CP-31398. CP-31398 and Prima-1 induced wt-p53
in lung tumors, with CP-31398 showing greater wt-p53 induction
as compared with Prima-1. No changes in expression of mut-p53
Figure 2. Effect of dietary feeding of p53 modulators on NNK-induced lung tumor growth in A/J mice. (A) Lungs with lesions from
different groups at the 20-week stage [(i) control, (ii) 100 ppm CP-31398, and (iii) 300 ppm Prima-1]. (B) Lungs with lesions from different
groups at the 37-week stage [(i) control, (ii) 100 ppm CP-31398, and (iii) 300 ppm Prima-1]. (C and D) Effect of CP-31398 and Prima-1 on
lung adenoma and adenocarcinoma formation after NNK treatment at the 20-week stage. Values are means ± SD with N = 10. The
significance of differences between control and treatment groups was analyzed by one-tailed t test with Welch correction and 95%
confidence interval. (E and F) Effect of CP-31398 and Prima-1 on lung adenoma formation at the 37-week stage. Values are means
± SD with N = 15. The significance of differences between control and treatment groups was analyzed by one-tailed t test with Welch
correction and 95% confidence interval.
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were detectable with either of the drugs, possibly because this mut-p53
antibody may recognize both wt-p53 and mut-p53 proteins under
the denaturing conditions of the gel.
CP-31398 and Prima-1 Decrease the Phosphorylation of Rb
Members of Rb protein are phosphorylated by cyclin-dependent
kinases (Cdks), leading to the activation of gene expression required
for cell cycle progression and proliferation. Because p21 is an inhib-
itor of Cdks, we investigated whether p53 modulators modified the
phosphorylation status of endogenous Rb protein. As shown in
Figure 5B, CP-31398 and Prima-1 inhibited phosphorylation of
Rb at Ser-795, but the total Rb protein levels were unaltered.
CP-31398 caused greater inhibition of Rb phosphorylation than
did Prima-1.
Discussion
The NNK-induced mouse lung tumor model has been well estab-
lished in studies of adenocarcinoma development, including chemo-
prevention [28–32]. High frequency of p53 mutations in lung cancer
has led us to investigate the effects of direct-acting small molecules
that rescue and activate mut-p53 for the prevention of lung cancer
induced by the tobacco carcinogen NNK in female A/J mice. Here,
Figure 3. IHC staining of lung adenocarcinomas for different markers after 37 weeks with p53 modulators. Representative lung sections
from the NNK-treated control group and from 100-ppm CP-31398 and 300-ppm Prima-1 treatment groups. Data are presented as means
± SEM; significance was analyzed by t test. (A) H&E: Images of H&E-stained lung sections from various groups. (B) TUNEL assay: In situ
apoptotic cells were identified by brown staining for TUNEL-positive cells, with methyl green for counterstain. A significant induction of
apoptosis was observed in adenocarcinomas of mice treated with CP-31398 or Prima-1 as compared with those from untreated control
mice. (C) PCNA: Cell proliferation index was measured by staining with PCNA antibody and counterstaining with hematoxylin. A sig-
nificant difference was observed in proliferative index with high PCNA expression in lung adenocarcinomas from NNK-treated groups
and very low expression in those from CP-31398– and Prima-1–treated groups. Data are expressed as a percent of NNK control (P< .05).
(D) p21: Paraffin sections of lung adenocarcinomas were subjected to IHC analysis using an anti-p21 antibody. There is intense stain-
ing of p21 in CP-31398– and Prima-1–treated groups compared with NNK control. (E) mut-p53: IHC staining of lung adenocarcinomas
for mut-p53. Intense brown staining observed in controls is absent in the mice administered diets containing CP-31398 or Prima-1.
(F) wt-p53: IHC staining of lung adenocarcinomas with wt-p53 monoclonal antibody. (G) Apoptotic index: Effect of CP-31398 and
Prima-1 on NNK-induced lung tumor apoptotic index at the 36-week stage: Values are the means ± SEM, and significant difference
between control and treatment groups was analyzed by t test. (H) Proliferative index: Effect of CP-31398 and Prima-1 on NNK-induced
lung tumor proliferative index at the 36-week stage: Values are the means ± SEM, and significant difference between control and
treatment groups was analyzed by t test.
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we demonstrated that both CP-31398 and Prima-1 were well toler-
ated and lacked overt toxicities. Chronic exposure to nontoxic doses
of each agent provided significant inhibition of lung adenocarcinoma
(47% to 72%; P < .0001) and decreased tumor volume (Figure 2).
In the last few decades, extensive efforts have been made to develop
direct targeting approaches, including gene therapy using viral vectors
and peptide molecules, for rescue of endogenous mutated tumor sup-
pressors [18,35–37]. The use of small molecules that rescue mut-p53
and enhance the wt-p53 activity would lend itself to effective inter-
vention, including prevention and/or delay of onset of cancers in
which p53 is likely to play a causative role. Re-expression of functional
p53 and/or activation of p53 has been shown to induce apoptosis
and growth arrest of cells undergoing neoplastic transformation
[38,39]. Our previous observations on chemically induced and spon-
taneous models of colon cancer [24,25], including skin tumorigenesis
[40], demonstrated significant efficacy of p53 modulators.
We found increased expression of wt-p53 and its nuclear localiza-
tion on treatment with direct-acting p53-modulating agents shown
by histologic and Western blot analyses, although we failed to ob-
serve significant changes in mut-p53 expression in NNK-induced
lung adenocarcinomas and/or with p53 modulatory agent treatments
(Figures 3 4 5). It is possible that the mut-p53 antibody may not be
able to recognize NNK-induced p53 mutant forms or very low levels
of p53 mutations. Our results suggest that CP-31398 and Prima-1
may induce wt-p53 expression, leading to suppression of lung tumor
inhibition that is supported by our study and other studies in in vitro
and in vivo models of other cancers [18,24–27].
To identify specific molecular alterations that may contribute to
the protective effect of p53 modulators in NNK-induced lung cancer
of A/J mice, we examined the expression of downstream effector
molecules that modulate cell proliferation. Here, we observe that
p21WAF1/CIP1 was expressed at very low levels in tumors of mice fed a
control diet, whereas its expression was upregulated by two- to three-
fold in the CP-31398– and Prima-1–fed mice.We also found decreased
levels of pRb without influencing total Rb protein expression levels in
lung tumors in mice fed CP-31398–containing diet. The induction of
p21WAF1/CIP1 by CP-31398 treatment can inhibit the formation of
one Cdk complex, and this, in turn, could be responsible for reduced
phosphorylation of Rb. Our results are in agreement with studies
carried out by Takimito et al. [20], where they show that CP-31398
inhibits pRb in a panel of human cancer cell lines.
We observed a significant up-regulation of TUNEL-positive cells,
as well as cleavage of caspase-3, in lung tumors from the mice fed
CP-31398 and Prima-1 (Figures 3 and 5), suggesting that p53-
induced apoptotic effects are mediated, in part, through the induc-
tion of caspase-3 and PARP cleavage. In support of this conclusion,
we have previously shown that CP-31398 inhibition of intestinal
tumors in APCmin/+ mice is associated with induction of wt-p53 and
caspase-3 and PARP cleavage [24]. However, Prima-1 exposure led to
induction of apoptosis in lung tumors but did not show any cleavage
of caspase-3, suggesting involvement of different mechanisms. Pre-
vious reports suggest that Prima-1 potentiated the effect of adriamycin
and triggers an apoptotic response in non–small cell lung cancer cells
[26]. Prima-1 also inhibited tumor cell growth in vivo in mice carrying
Figure 4.Modulation by p53 modulators of wt-p53 and mut-p53 expression and localization in lung adenocarcinomas. Monoclonal anti-
bodies were used in connection with TRITC red–conjugated secondary antibody. 4′,6-Diamidino-2-phenylindole (blue signal) was used
for counterstaining of the nucleus. The images were representative of three experiments (original magnification, ×400; a merged figure
is shown at ×1.2 the original). The arrows in the merged figure indicate locations of increased wt-p53 and apoptosis in the nucleus of
a tumor cell from a CP-31398 (100 ppm)–treated mouse compared to the nucleus from a control tumor. Even in the Prima-1 group, there
is intense staining of wt-p53 and we could not find any apoptotic cells. We could not distinguish or localize the mut-p53 distribution.
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endogenous missense mutations in p53 [27]. Previous studies have
shown that the PCNA labeling index is high in human lung tumors
and the bronchial epithelial cells of smokers [41,42]. Dietary adminis-
tration of both p53 modulators decreased the size of the lung tumors
as well as the PCNA labeling index as compared with those in mice
fed the control diet (Figures 2 and 3).
In summary, this is the first report on the chemopreventive effects
of CP-31398 and Prima-1 on NNK-induced lung carcinogenesis
in the A/J mouse strain. Both chemopreventive agents were able to
inhibit adenocarcinoma multiplicity and tumor size whether mice were
exposed to either short term or long term. Our observations suggest
that p53-modulating agents delay the adenoma to adenocarcinoma
progression, and there is ∼30% to 50% inhibition (adenoma +
adenocarcinoma) in the treatment groups when compared to control
diet–fed mice. These results clearly suggest that some of the NNK-
induced lung lesions may not even progress to adenomas or that in
turn to adenocarcinomas. There is relatively less adenocarcinoma
inhibition at the 34-week stage compared to the 17-week stage, sug-
gesting that even in treatment groups several adenomas had progressed
to adenocarcinomas, indicating that these adenocarcinomas might
escape the tumor inhibitory effect of p53 modulators. Our observa-
tions suggest a substantial delay of adenoma progression to adenocar-
cinomas and relatively lesser tumor cell growth in adenocarcinomas
in mice exposed to p53 modulators at 34 weeks. The biomarkers
we have analyzed on lung tumor proliferation and apoptosis at
34 weeks support tumor growth inhibitory effects of p53-modulating
agents. However, in-depth molecular pathway analysis is required to
address why some adenomas escape and progress to adenocarcinomas.
Our results suggest that some of the NNK-induced lung lesions may
not even progress to adenomas in the treatment groups, in addition to
progression delay as discussed above. Thus, p53-modulating agents
favor tumor prevention. In support of this view, our previous studies
suggest that early and continuous intervention with CP-31398 provides
better efficacy and that combining with other preventive agents also
improve the colon adenocarcinoma inhibitory effects [24,25]. Fur-
thermore, our unpublished data suggest that the administration of
CP-31398 at late adenoma and adenocarcinoma stage had modest
efficacy effects in rat colon cancer model. More recently, we have
shown that CP-31398 administration inhibits the progression of
low-grade papillary transitional cell carcinomas to invasive transi-
tional cell carcinomas [43]. Thus, p53 modulators may block the
NNK-induced adenoma formation and also progression of adenoma/
adenocarcinoma growth.
In the present study, we have observed a nonstatistically signifi-
cant reduction of spontaneous lung tumors in mice exposed to p53-
modulating agents. Previous studies by the group of Dr Ming You
Figure 5. Immunoblot analyses of lung tumor lysates derived from A/J mice treated with NNK control (C), 50 or 100 ppm CP-31398
(low-dose and high-dose CP-31398, respectively), or 150 or 300 ppm Prima-1 (low-dose and high-dose Prima-1, respectively) and sacrificed
after 20 or 37 weeks of treatment. (A) Expression of p21, wt-p53, mut-p53, and β-actin after 20 weeks with p53 modulators. (B) Expression
of p21, wt-p53, mut-p53, pRb–Ser-795, total Rb, PARP, and cleaved caspase-3 protein from lung tumor samples of A/J mice administered
50 or 100 ppm CP-31398 or 150 or 300 ppm Prima-1 for 37 weeks. Lung tumor tissue lysates were homogenized in lysis buffer and
subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis followed by Western blot analysis as described in Materials
and Methods section. Nitrocellulose was probed with primary antibodies specific for p53, p21CIP1, cleaved caspase-3, and cleaved PARP
and then incubated with appropriate peroxidase-conjugated secondary antibodies. Proteins were visualized with enhanced chemi-
luminescence detection system.
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[44–46] have reported the role of p53 in A/J mice lung tumorigenesis
with spontaneous and NNK-treated mice. These studies suggest that
there is no significant difference (modest risk) in lung spontaneous
tumors in dominant mutant A/Jp53Val135 mice compared to wild-
type mice, whereas there is a two- to three-fold increase risk of NNK-
induced lung tumors in A/Jp53Val135 mice compared to wild-type
NNK-treated mice, thus suggesting the limited role of p53 in spon-
taneous lung tumors of A/J mice compared to the highly significant
role of p53 in tobacco carcinogen–induced lung tumor development.
In our study, we observed that there is no significant difference in
lung spontaneous tumors in mice fed with control diet (adenomas,
0.4 ± 0.55/mouse; N = 6) compared to mice fed with CP-31398 and
Prima-1 (adenomas, 0.2 ± 0.45; P = .27). Overall, results from the
present study suggest that CP-31398 and Prima-1 can delay progres-
sion of NNK-induced lung adenoma formation and delay the adenoma
progression to adenocarcinomas. Oral administration of nontoxic
p53-modulating small molecules may provide a promising approach
for the prevention of lung cancer in individuals at high risk, both
ex-smokers and current smokers.
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